New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:14 EDTJNJFDA approves label change for Doribax describing increased risk of death
The FDA announced it has concluded that Doribax, an antibacterial drug that has been used to treat patients who develop pneumonia while on ventilators, carries an increased risk of death and lower clinical cure rates compared to use of imipenem and cilastatin for injection, marketed in the U.S. under the name Primaxin. "Based on our analysis of data from a three-year clinical trial that was prematurely stopped in 2011 due to these safety concerns, we have approved changes to the Doribax drug label that describe these risks," the FDA stated. The FDA said Doribax is still considered safe and effective for its FDA-approved indications - treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections. Doribax is marketed outside Japan by Johnson & Johnson.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
11:39 EDTJNJBass denied request for review of Biogen multiple sclerosis drug patent
Subscribe for More Information
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
August 25, 2015
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use